You have 9 free searches left this month | to do more

venetoclax

Venetoclax is a drug used to treat Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and other conditions. Venetoclax is being actively studied in 234 studies and prior, has been studied in 25.

Top SponsorsTop SitesTop Investigators
AbbVieM D Anderson Cancer CenterMatthew S. Davids, MD
M.D. Anderson Cancer CenterMD Anderson Cancer CenterPaolo Ghia
Hoffmann-La RocheDana Farber Cancer InstituteAndrew Lane
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Edmonton, Alberta, Canada
  • +1 more
2021-11-29
Nov 29, 2021
B
Not yet recruiting
  • Relapsed Non Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Loncastuximab tesirine
  • Venetoclax
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cance
2021-12-20
Dec 20, 2021
K
Available
  • Relapsed Childhood ALL
  • Relapsed Childhood Lymphoblastic Lymphoma
  • Dallas, Texas
    University of Texas Southwestern Medical Center
2022-02-28
Feb 28, 2022
C
Suspended
  • Non-hodgkin Lymphoma
  • Venetoclax
  • Cleveland, Ohio
  • +1 more
2021-11-03
Nov 3, 2021
D
Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • Venetoclax
  • +2 more
  • Boston, Massachusetts
  • +1 more
2021-10-19
Oct 19, 2021
G
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Venetoclax
  • +2 more
  • Washington, District of Columbia
  • +1 more
2022-03-14
Mar 14, 2022
E
Recruiting
  • CCND1 Positive
  • +2 more
  • Atlanta, Georgia
  • +2 more
2022-02-09
Feb 9, 2022
U
Recruiting
  • Relapsed or Refractory Hematologic Malignancies
  • Chicago, Illinois
    University of Illinois Cancer Center
2022-01-28
Jan 28, 2022
M
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-15
Mar 15, 2022
O
Recruiting
  • Chronic Lymphocytic Leukemia
  • Ibrutinib Resistance
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-10-29
Oct 29, 2021
P
Recruiting
  • Diffuse Large B-cell-lymphoma
  • Venetoclax
  • +4 more
  • Saint Louis, Missouri
  • +2 more
2022-01-26
Jan 26, 2022
J
Recruiting
  • Acute Myeloid Leukemia (AML)
  • +4 more
  • Venetoclax
  • +4 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2022-01-21
Jan 21, 2022
M
Not yet recruiting
  • Leukemia, Myeloid, Acute
  • +5 more
  • Venetoclax
  • +2 more
  • Melbourne, Victoria, Australia
    Melbourne Health
2022-03-16
Mar 16, 2022
C
Not yet recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Copanlisib Hydrochloride
  • Venetoclax
  • Duarte, California
  • +1 more
2022-03-07
Mar 7, 2022
N
Suspended
  • Acute Myeloid Leukemia
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2022-04-05
Apr 5, 2022
H
Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax
  • Helsinki, Uusimaa, Finland
    HelsinkiUCH
2021-08-24
Aug 24, 2021
F
Not yet recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-31
Mar 31, 2022
M
Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • Leukemia
  • Houston, Texas
    MD Anderson Cancer Center
2022-03-07
Mar 7, 2022
M
Recruiting
  • Acute Myeloid Leukemia
  • Duarte, California
  • +2 more
2022-01-21
Jan 21, 2022
D
Recruiting
  • Leukemia
  • Venetoclax
  • Standard Chemotherapy
  • Boston, Massachusetts
  • +1 more
2021-08-02
Aug 2, 2021
S
Terminated
  • Non-Hodgkin Lymphoma
  • Basel, Switzerland
  • +5 more
2022-03-18
Mar 18, 2022
A
Not yet recruiting
  • Acute Myeloid Leukemia
  • Relapsed Adult AML
  • Lintuzumab-Ac225
  • +2 more
  • (no location specified)
2022-02-22
Feb 22, 2022